Precision Optics Corporation, Inc.
POCI Nasdaq Electromedical & Electrotherapeutic Apparatus Financials FY2017βFY2026
What Precision Optics Corporation, Inc. does
No business description yet.
- Legal name
- PRECISION OPTICS CORPORATION, INC.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K Β· Sep 28, 2026
- Accession Β· CIK
- 0001683168-26-007462
0000867840
Revenue and margins
Precision Optics Corporation, Inc. had $31.5M of revenue in fiscal 2026, up 65.2% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$2.0M in fiscal 2026, β6.3% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Precision Optics Corporation, Inc. returned β to shareholders in fiscal 2026. The diluted share count rose 25.6%.
Balance sheet
Cash, debt and the ratios that show how comfortably Precision Optics Corporation, Inc. can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $0.6M | $2.9M | $0.4M | $1.8M | $9.8M |
| Debt incl. finance leases | $2.5M | $2.7M | $2.2M | $1.9M | $1.3M |
| Debt / equity | 0.3x | 0.2x | 0.2x | 0.2x | 0.1x |
| Interest coverage | β9.7x | β2.9x | β12.1x | β24.5x | β23.7x |
| Current ratio | 1.4x | 1.9x | 1.5x | 1.6x | 2.3x |
| Quick ratio | 0.8x | 1.3x | 0.9x | 1.1x | 1.8x |
| Total assets | $16.7M | $19.7M | $16.9M | $19.8M | $32.3M |
| Total liabilities | $7.7M | $7.7M | $6.8M | $7.5M | $12.0M |
| Shareholders' equity | $9.0M | $12.0M | $10.1M | $12.3M | $20.3M |
| Net debt (β = net cash) | $1.9M | β$0.2M | $1.8M | $0.2M | β$8.5M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 2 / 8 | 3 / 8 | 5 / 8 | 1 / 9 | 6 / 9 | 3 / 9 | 3 / 9 | 5 / 9 |
| Accruals ratio | β18.8% | β21.0% | 8.3% | β12.0% | β2.4% | 0.0% | β0.3% | β1.5% | β13.0% | β8.0% |
| Altman Z'' | β82.39 | β57.81 | β17.13 | β22.99 | β21.88 | β8.02 | β5.01 | β8.55 | β8.27 | β2.77 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $3.2M | $4.0M | $6.8M | $9.9M | $10.7M | $15.7M | $21.0M | $19.1M | $19.1M | $31.5M |
| Gross profit | $0.8M | $1.5M | $2.1M | $3.4M | $3.4M | $4.9M | $7.7M | $5.8M | $3.4M | $5.4M |
| Research and development | $0.5M | $0.5M | $0.5M | $0.9M | $0.6M | $0.7M | $1.0M | $1.0M | $1.2M | $1.0M |
| Operating income | β$1.0M | β$0.3M | β$0.6M | β$1.4M | β$0.9M | β$1.5M | β$0.6M | β$2.7M | β$5.6M | β$3.5M |
| Interest expense | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.2M | $0.2M | $0.2M | $0.2M | $0.1M |
| Pretax income | β$1.0M | β$0.4M | β$0.6M | β$1.4M | β$0.1M | β$0.9M | β$0.1M | β$2.9M | β$5.8M | β$3.6M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$1.0M | β$0.4M | β$0.6M | β$1.4M | β$0.1M | β$0.9M | β$0.1M | β$3.0M | β$5.8M | β$3.6M |
| Net income to common | β | β | β | β | β$0.1M | β$0.9M | β$0.1M | β$3.0M | β$5.8M | β$3.6M |
| Diluted EPS | β$0.12 | β$0.04 | β$0.05 | β$0.11 | β$0.01 | β$0.18 | β$0.03 | β$0.49 | β$0.85 | β$0.43 |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | β$0.7M | $0.1M | β$1.0M | β$0.6M | $0.0M | β$0.9M | β$0.1M | β$2.7M | β$3.4M | β$1.6M |
| Capital expenditure | $0.0M | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M | $0.0M | $0.3M | $0.2M | $0.4M |
| Free cash flow | β$0.7M | $0.1M | β$1.2M | β$0.7M | β$0.0M | β$1.0M | β$0.1M | β$3.0M | β$3.6M | β$2.0M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.2M | $0.2M | $0.2M | $0.2M | $0.3M |
| Stock-based compensation | $0.2M | $0.1M | $0.3M | $0.5M | $0.7M | $0.9M | $0.9M | $1.0M | $1.6M | $1.1M |
| Acquisitions | β | β | $0.0M | $1.4M | $0.2M | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.1M | $0.4M | $2.3M | $1.1M | $0.9M | $0.6M | $2.9M | $0.4M | $1.8M | $9.8M |
| Total debt | β | β | β | β | $0.0M | $2.4M | $2.7M | $2.2M | $1.9M | $1.3M |
| Finance lease liabilities | β | β | β | β | β | $0.2M | β | β | β | β |
| Current assets | $1.7M | $2.4M | $6.4M | $4.9M | $4.8M | $6.5M | $9.9M | $7.1M | $10.1M | $20.1M |
| Current liabilities | $1.2M | $1.9M | $3.6M | $3.1M | $2.5M | $4.6M | $5.3M | $4.9M | $6.2M | $8.8M |
| Inventory | $1.1M | $1.1M | $1.7M | $2.2M | $1.9M | $3.0M | $2.8M | $2.9M | $3.6M | $3.8M |
| Property and equipment, net | $0.1M | $0.0M | $0.4M | $0.5M | $0.6M | $0.6M | $0.4M | $0.5M | $0.5M | $0.9M |
| Goodwill | β | $0.0M | $0.7M | $0.7M | $0.7M | $8.8M | $8.8M | $8.8M | $8.8M | $8.8M |
| Intangible assets | $0.0M | $0.0M | $0.1M | $0.1M | $0.1M | $0.2M | $0.3M | $0.3M | $0.2M | $0.2M |
| Total assets | $1.8M | $2.5M | $7.5M | $6.4M | $6.3M | $16.7M | $19.7M | $16.9M | $19.8M | $32.3M |
| Total liabilities | $1.2M | $1.9M | $4.1M | $3.6M | $2.8M | $7.7M | $7.7M | $6.8M | $7.5M | $12.0M |
| Shareholders' equity | $0.6M | $0.6M | $3.4M | $2.8M | $3.4M | $9.0M | $12.0M | $10.1M | $12.3M | $20.3M |
| Margins | ||||||||||
| Gross margin | 24.5% | 36.7% | 31.2% | 33.9% | 32.2% | 31.4% | 36.8% | 30.3% | 17.8% | 17.2% |
| Operating margin | β31.8% | β8.6% | β9.0% | β14.3% | β8.5% | β9.7% | β3.0% | β14.3% | β29.1% | β11.1% |
| EBITDA margin | β30.7% | β8.0% | β8.4% | β13.2% | β7.1% | β8.4% | β2.0% | β13.1% | β28.0% | β10.2% |
| Net margin | β31.9% | β8.7% | β9.0% | β14.4% | β1.0% | β5.9% | β0.7% | β15.4% | β30.3% | β11.5% |
| FCF margin | β22.0% | 2.4% | β17.2% | β7.2% | β0.3% | β6.7% | β0.5% | β15.5% | β19.0% | β6.3% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β27.8% | β11.2% | β4.3% | β18.1% | β35.3% | β23.4% |
| Return on capital employed | β172.3% | β60.2% | β15.8% | β44.4% | β24.1% | β12.5% | β4.4% | β22.7% | β40.7% | β14.9% |
| Return on equity | β180.2% | β62.6% | β31.2% | β46.4% | β3.3% | β15.0% | β1.4% | β26.7% | β51.8% | β22.3% |
| Return on assets | β55.9% | β16.3% | β12.3% | β20.6% | β1.6% | β8.1% | β0.8% | β16.1% | β31.5% | β13.9% |
| Return on tangible equity | β190.5% | β68.0% | β23.3% | β71.7% | β4.0% | β | β4.9% | β308.4% | β180.5% | β32.1% |
| Growth | ||||||||||
| Revenue growth | β | 28.0% | 68.5% | 45.8% | 7.6% | 46.9% | 34.2% | β9.2% | β0.1% | 65.2% |
| FCF growth | β | β | β1,316.7% | β | β | β | β | β | β | β |
| Share count change | β | 17.8% | 16.9% | 13.2% | 2.2% | β60.1% | 7.0% | 7.1% | 11.9% | 25.6% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | 0.0x | 0.3x | 0.2x | 0.2x | 0.2x | 0.1x |
| Interest coverage | β323.4x | β183.5x | β437.5x | β1,423.0x | β170.9x | β9.7x | β2.9x | β12.1x | β24.5x | β23.7x |
| Current ratio | 1.4x | 1.2x | 1.8x | 1.6x | 1.9x | 1.4x | 1.9x | 1.5x | 1.6x | 2.3x |
| Quick ratio | 0.5x | 0.7x | 1.3x | 0.9x | 1.2x | 0.8x | 1.3x | 0.9x | 1.1x | 1.8x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.9% | 0.1% | 2.1% | 1.2% | 0.7% | 0.7% | 0.1% | 1.4% | 1.2% | 1.4% |
| Stock comp / revenue | 6.4% | 1.3% | 3.9% | 5.1% | 6.9% | 5.8% | 4.4% | 5.0% | 8.4% | 3.6% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 2.0 | 3.0 | 5.0 | 1.0 | 6.0 | 3.0 | 3.0 | 5.0 |
| Altman Z'' | β82.4 | β57.8 | β17.1 | β23.0 | β21.9 | β8.0 | β5.0 | β8.5 | β8.3 | β2.8 |
| Accruals ratio | β18.8% | β21.0% | 8.3% | β12.0% | β2.4% | 0.0% | β0.3% | β1.5% | β13.0% | β8.0% |
Source: SEC EDGAR XBRL filings (CIK 0000867840). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.